home / stock / btx / btx news

BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 09/09/21

Stock Information
Company Name: Brooklyn ImmunoTherapeutics Inc.
Stock Symbol: BTX
Market: NYSE
Website: biotimeinc.com
Menu
BTX BTX Quote BTX Short BTX News BTX Articles BTX Message Board
Get BTX Alerts

News, Short Squeeze, Breakout and More Instantly...
BTX - Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...
BTX - Brooklyn ImmunoTherapeutics: Can It GameStop Again?

BTX had its gamestopping moment in April, rising nearly 20x. The company took the opportunity to raise some cash and improve their profile. Today, it has a much larger float, low short interest, and stronger fundamentals. For further details see: Brooklyn ImmunoTherapeut...

BTX - Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...

BTX - Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorder...
BTX - Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET

BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood di...

BTX - Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Summer Virt...

BTX - Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorder...
BTX - Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021

NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorder...

BTX - Brooklyn Immuno Reports Inducement Grants

BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorde...

BTX - Brooklyn ImmunoTherapeutics completes acquisition of Novellus Therapeutics

Brooklyn ImmunoTherapeutics ([[BTX]] -4.5%) has completed its acquisition of Novellus Therapeutics.The transaction advances Brooklyn’s evolution into a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine programs. Key transaction highlight...
Previous 10 Next 10